The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
New role strengthens Quantori’s global leadership position in data science & digital IT
Subscribe To Our Newsletter & Stay Updated
